Basic Information
Ontozry
Regulatory Information
EMEA/H/C/005377
March 26, 2021
10
December 18, 2024
Company Information
rome – italy
Angelini Pharma S.p.A Viale Amelia 70, 00181
Angelini Pharma SpA
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
Overview Summary
Ontozry is an epilepsy medicine for treating epileptic fits starting in one specific part of the brain (focal seizures), including those that eventually spread to the whole brain (secondary generalisation). Ontozry is used as an add-on to other epilepsy medicines for adults with seizures that are not controlled despite having tried at least two other treatments. It contains the active substance cenobamate.